Literature DB >> 31323243

Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.

Kelsey A Hopkins1, Nicole Vike2, Xin Li1, Jacqueline Kennedy1, Emma Simmons1, Joseph Rispoli3, Luis Solorio4.   

Abstract

In situ forming implants (ISFIs) form a solid drug-eluting depot, releasing drug for an extended period of time after a minimally-invasive injection. Clinical use of ISFIs has been limited because many factors affect drug release kinetics. The aim of this study was to use diffusion-weighted MRI (DWI) to noninvasively quantify spatial-temporal changes in implant diffusivity in situ. ISFIs were formed using poly(lactic-co-glycolic) acid, with a molecular weight of either 15 kDa or 52 kDa, and fluorescein as the mock drug. Drug release, polymer erosion, polymer degradation, and implant diffusivity were analyzed in vitro over 21 days. DWI was also performed in vivo over 5 days. Spatial diffusivity maps of the implant were generated using DWI data. Results showed constant diffusivity at the implant shell ((1.17 ± 0.13) × 10-3 mm2/s) and increasing diffusivity within the interior over time (from (0.268 ± 0.081) × 10-3 mm2/s during day 1 to (1.88 ± 0.04) × 10-3 mm2/s at 14 d), which correlated with increasing porosity of the implant microstructure. Implants formed in vivo followed the same diffusivity trend as those in vitro. This study validates the use of DWI to provide novel functional information about implant behavior through its ability to noninvasively characterize transport properties within the implant both in vitro and in vivo.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Controlled release; Diffusion-weighted imaging; Diffusivity; Drug delivery; MRI; in situ forming implants

Year:  2019        PMID: 31323243      PMCID: PMC6815723          DOI: 10.1016/j.jconrel.2019.07.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

Review 1.  Injectable implants for the sustained release of protein and peptide drugs.

Authors:  Priyanka Agarwal; Ilva D Rupenthal
Journal:  Drug Discov Today       Date:  2013-02-11       Impact factor: 7.851

2.  MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders.

Authors:  D Le Bihan; E Breton; D Lallemand; P Grenier; E Cabanis; M Laval-Jeantet
Journal:  Radiology       Date:  1986-11       Impact factor: 11.105

3.  Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems.

Authors:  Ravi B Patel; Angela N Carlson; Luis Solorio; Agata A Exner
Journal:  J Biomed Mater Res A       Date:  2010-08       Impact factor: 4.396

4.  Patient medication adherence: measures in daily practice.

Authors:  Beena Jimmy; Jimmy Jose
Journal:  Oman Med J       Date:  2011-05

5.  Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer.

Authors:  K J Brodbeck; J R DesNoyer; A J McHugh
Journal:  J Control Release       Date:  1999-12-06       Impact factor: 9.776

6.  Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.

Authors:  Yu Sun; Henrik Jensen; Nickolaj J Petersen; Susan W Larsen; Jesper Østergaard
Journal:  J Pharm Biomed Anal       Date:  2017-12-02       Impact factor: 3.935

7.  Injectable poly(lactic-co-glycolic) acid scaffolds with in situ pore formation for tissue engineering.

Authors:  Melissa D Krebs; Kathleen A Sutter; Angela S P Lin; Robert E Guldberg; Eben Alsberg
Journal:  Acta Biomater       Date:  2009-05-04       Impact factor: 8.947

8.  Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process.

Authors:  Sabine Kempe; Hendrik Metz; Karsten Mäder
Journal:  J Control Release       Date:  2008-06-17       Impact factor: 9.776

9.  Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy.

Authors:  Sabine Kempe; Hendrik Metz; Priscila G C Pereira; Karsten Mäder
Journal:  Eur J Pharm Biopharm       Date:  2009-06-21       Impact factor: 5.571

Review 10.  Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.

Authors:  Amir Fakhari; J Anand Subramony
Journal:  J Control Release       Date:  2015-11-14       Impact factor: 9.776

View more
  2 in total

1.  A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.

Authors:  Manse Kim; Claire E Johnson; Alan A Schmalstig; Ayano Annis; Sarah E Wessel; Brian Van Horn; Amanda Schauer; Agata A Exner; Jason E Stout; Angela Wahl; Miriam Braunstein; J Victor Garcia; Martina Kovarova
Journal:  Nat Commun       Date:  2022-08-08       Impact factor: 17.694

2.  Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.

Authors:  Jordan B Joiner; Jasmine L King; Roopali Shrivastava; Sarah Anne Howard; Mackenzie L Cottrell; Angela D M Kashuba; Paul A Dayton; Soumya Rahima Benhabbour
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.